Stocks · News reference
Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Atara Biotherapeutics Q2 EPS $(0.32), Inline, Sales $630.000K Beat $366.667K Estimate
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 268.42 percent decrease over earnings of $0.19 per share from the same period last
8-K filing — Atara Biotherapeutics, Inc. (ATRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346857 Size: 455 KB Item 2.02: Results of Operations and Financial Condition